{"id":741150,"date":"2023-03-20T08:10:07","date_gmt":"2023-03-20T12:10:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/"},"modified":"2023-03-20T08:10:07","modified_gmt":"2023-03-20T12:10:07","slug":"rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/","title":{"rendered":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit"},"content":{"rendered":"

<\/p>\n

RG6501 (OpRegen\u00ae<\/sup>) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit<\/b><\/p>\n

CARLSBAD, Calif.–(BUSINESS WIRE<\/a>)–Lineage Cell Therapeutics, Inc.<\/a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1\/2a clinical study of RG6501 (OpRegen<\/a>), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit<\/a>, organized by the Foundation Fighting Blindness<\/a> and the Oregon Health & Science University Casey Eye Institute<\/a>. The meeting will be held April 21st<\/sup>, 2023, at the Marriott New Orleans Warehouse Arts District in New Orleans, LA. The presentation, \u201cPhase 1\/2a Study of OpRegen in Patients with Geographic Atrophy (GA),\u201d<\/i> will be presented by Eyal Banin, M.D., Ph.D.<\/a>, Director, Center for Retinal and Macular Degenerations (CRMD), Department of Ophthalmology at Hadassah-Hebrew University Medical Center<\/a>. RG6501 (OpRegen) is a retinal pigment epithelium cell transplant therapy currently in development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). It is being developed under an exclusive worldwide collaboration<\/a> between Lineage, and Roche<\/a> and Genentech<\/a>, a member of the Roche Group, and is currently being evaluated<\/a> in a Phase 2a clinical study<\/a> in patients with geographic atrophy secondary to age-related macular degeneration (ClinicalTrials.gov Identifier: NCT05626114).\n<\/p>\n

\nThe 2023 Retinal Cell and Gene Therapy Innovation Summit<\/a>, “Defining the Preclinical to Clinical Roadmap” will feature presentations that emphasize clinical trial design for gene and cell-based therapies. Representatives from the biotech and pharma industries will come together with physicians and scientists to discuss rapidly emerging ocular gene and cell therapies and strategize how to move the most advanced retinal disease therapy options forward.\n<\/p>\n

About the Foundation Fighting Blindness<\/b><\/p>\n

\nThe Foundation Fighting Blindness<\/a> was established in 1971 by a passionate group of families driven to find treatments and cures for inherited retinal diseases that were affecting their loved ones. Today, the Foundation Fighting Blindness is the world\u2019s leading private funder of retinal disease research. That funding has been a driving force behind the progress toward cures, including the identification of more than 270 genes linked to retinal disease, and the launch of over 40 clinical trials for potential treatments. For more information, please visit https:\/\/www.fightingblindness.org\/<\/a> or follow the association on Twitter @FightBlindness<\/a>.\n<\/p>\n

About Geographic Atrophy<\/b><\/p>\n

\nGeographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterized by severe loss of visual function. GA is a leading cause of adult blindness in the developed world, affecting at least 5 million people globally. There are two forms of advanced AMD: neovascular AMD and GA. GA and neovascular AMD can occur simultaneously in the same eye, and patients treated for neovascular AMD may still go on to develop GA. GA typically affects both eyes.\n<\/p>\n

About Lineage Cell Therapeutics, Inc.<\/b><\/p>\n

\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage\u2019s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage\u2019s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (\u201coff-the-shelf\u201d) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed<\/a> under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1\/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage\u2019s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com<\/a> or follow the company on Twitter @LineageCell<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230320005164\/en\/<\/a><\/span><\/p>\n

Lineage Cell Therapeutics, Inc. IR
\n<\/b>
Ioana C. Hone
\n
(ir@lineagecell.com<\/a>)
\n
(442) 287-8963\n<\/p>\n

LifeSci Advisors
\n<\/b>
Daniel Ferry
\n
(daniel@lifesciadvisors.com<\/a>)
\n
(617) 430-7576\n<\/p>\n

Russo Partners \u2013 Media Relations
\n<\/b>
Nic Johnson or David Schull
\n
(Nic.johnson@russopartnersllc.com<\/a>)
\n
(David.schull@russopartnersllc.com<\/a>)
\n
(212) 845-4242\n<\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research FDA Genetics Clinical Trials Biotechnology Pharmaceutical Health Optical Science Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1\/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute. The meeting will be held April 21st, 2023, at the Marriott New Orleans Warehouse Arts District in New Orleans, LA. The presentation, \u201cPhase 1\/2a Study of OpRegen in Patients with Geographic Atrophy (GA),\u201d will be presented by … <\/p>\n

Continue reading “RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-741150","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1\/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute. The meeting will be held April 21st, 2023, at the Marriott New Orleans Warehouse Arts District in New Orleans, LA. The presentation, \u201cPhase 1\/2a Study of OpRegen in Patients with Geographic Atrophy (GA),\u201d will be presented by … Continue reading "RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-20T12:10:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RG6501 (OpRegen\u00ae) Phase 1\\\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit\",\"datePublished\":\"2023-03-20T12:10:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/\"},\"wordCount\":804,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/\",\"name\":\"RG6501 (OpRegen\u00ae) Phase 1\\\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-03-20T12:10:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RG6501 (OpRegen\u00ae) Phase 1\\\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/","og_locale":"en_US","og_type":"article","og_title":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit - Market Newsdesk","og_description":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1\/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute. The meeting will be held April 21st, 2023, at the Marriott New Orleans Warehouse Arts District in New Orleans, LA. The presentation, \u201cPhase 1\/2a Study of OpRegen in Patients with Geographic Atrophy (GA),\u201d will be presented by … Continue reading \"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-20T12:10:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit","datePublished":"2023-03-20T12:10:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/"},"wordCount":804,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/","name":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-03-20T12:10:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230320005164r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rg6501-opregen-phase-1-2a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=741150"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741150\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=741150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=741150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=741150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}